Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Al-Ola Abdallah: Discussing Updates of CAR-T in Malignant Hematology with Nausheen Ahmed

26 days / oncodaily

J&J pours $1B into new cell therapy site in Pennsylvania

26 days / endpoints / Nicole DeFeudis

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

26 days / endpoints / Elizabeth Cairns

One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough

26 days / sciencedaily

Caroline Pothet: The 2026 Workplan of the Committee For Advanced Therapies is Available

27 days / oncodaily

Eddie Cliff: Why CAR T Infusion Timing Doesn’t Change Outcomes in LBCL

27 days / oncodaily

Optimizing CAR T-cell therapy to tackle solid tumors

28 days / medicalxpress

Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B

5 wks / medcitynews / Frank Vinluan

Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition

5 wks / endpoints / Kyle LaHucik

Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 4 wks

Related Stories

Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 14 days
Merck Eyes $30B Deal for Revolution Medicines Acquisition / 2 months
Merck acquires Cidara’s preventive flu drug for $9.2B / 4 months
Novartis pays $100M upfront for macrocyclic peptide platform / 23 days
Carolyn Bertozzi Returns to Eli Lilly Board / 3 months
Gilead to buy Arcellx for $7.8B, boosting cell therapy push / 21 days
Sanofi’s $2.2B Dynavax Acquisition Boosts Vaccine Portfolio / 2 months

Related Tags

Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (20 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

more #pharmaceuticals

Eli Lilly

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (8 days)

GLP‑1 drugs associated with lower addiction risk in large study (10 days)

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial (18 days)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.